ArticleMolecular and clinical oncology2016
Muscle wasting associated with the long-term use of mTOR inhibitors.
Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- The effect of rapamycin and its analogues on age-related musculoskeletal diseases: a systematic review.Aging clinical and experimental research · 2022Pooled it
- Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.Journal of cachexia, sarcopenia and muscle · 2021Pooled it
- Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.Internal and emergency medicine · 2021Pooled it
- Immunometabolic mechanisms of osteosarcopenic obesity: chronic inflammation, trained immunity, and systemic immune dysregulation.Frontiers in immunology · 2026Review
- AMPK/mTOR balance during exercise: implications for insulin resistance in aging muscle.Molecular and cellular biochemistry · 2025Review
- Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study.The oncologist · 2025Article
- Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group.Hepatology international · 2024Review
- Identification of ferroptosis-associated genes and potential pharmacological targets in sepsis-induced myopathy.Heliyon · 2024Article
- The Current Landscape of Pharmacotherapies for Sarcopenia.Drugs & aging · 2024Article
- Cancer cachexia: molecular mechanisms and treatment strategies.Journal of hematology & oncology · 2023Review
- Sarcopenic Obesity: Involvement of Oxidative Stress and Beneficial Role of Antioxidant Flavonoids.Antioxidants (Basel, Switzerland) · 2023Review
- Sarcopenia in chronic kidney disease: from bench to bedside.The Korean journal of internal medicine · 2023Review
- The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases.International journal of molecular sciences · 2022Review
- Article
- Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-α blocker.Journal of clinical biochemistry and nutrition · 2022Article
- Activation of Akt-mTORC1 signalling reverts cancer-dependent muscle wasting.Journal of cachexia, sarcopenia and muscle · 2022Article
- Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.Frontiers in pharmacology · 2022Review
- A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data.Frontiers in pharmacology · 2022Article
- Chemotherapy agents reduce protein synthesis and ribosomal capacity in myotubes independent of oxidative stress.American journal of physiology. Cell physiology · 2021Article
- Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some targeted therapies alter muscle mass due to interference with pathways of muscle metabolism. The effects of mammalian target of ra pamycin (mTOR) inhibitors on muscle mass have yet to be fully elucidated. In the present study, the computerized tomography (CT) scans of patients receiving mTOR inhibitors for at least 6 months taken at baseline and post-therapy were retrospectively retrieved, and body composition analyses were performed using the software, sliceOmatic version 5.0 (TomoVision, Inc., Magog, QC, Canada). The difference in body composition parameters was evaluated for significance. The time to treatment (TTF) failure was also compared between the sarcopenic and non-sarcopenic patients at the baseline. Of the 75 patients studied, 20 matched the inclusion criteria (including 16 males). The mean duration between the CT scans was 14.4±2.0 months. A total of 12 (60%) patients were sarcopenic at the baseline, whereas three more (75% in total) became sarcopenic following treatment. The use of mTOR inhibitors significantly decreased the skeletal muscle area (P=0.011) and lean body mass (P=0.007), although it had no effect on adipose tissue (P=0.163) or body weight (P=0.262). The rate of skeletal muscle wasting was 2.6 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.